Moors & Cabot Inc. reduced its position in shares of Abbott Laboratories (NYSE:ABT) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,694 shares of the healthcare product maker’s stock after selling 1,484 shares during the period. Moors & Cabot Inc.’s holdings in Abbott Laboratories were worth $3,580,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the stock. Capital Research Global Investors increased its stake in Abbott Laboratories by 45.7% in the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock worth $2,313,334,000 after purchasing an additional 14,918,038 shares in the last quarter. Janus Henderson Group PLC increased its stake in Abbott Laboratories by 3,373.9% in the 2nd quarter. Janus Henderson Group PLC now owns 7,874,473 shares of the healthcare product maker’s stock worth $382,779,000 after purchasing an additional 7,647,798 shares in the last quarter. BlackRock Inc. increased its stake in Abbott Laboratories by 3.3% in the 4th quarter. BlackRock Inc. now owns 110,201,384 shares of the healthcare product maker’s stock worth $6,289,191,000 after purchasing an additional 3,566,731 shares in the last quarter. Vanguard Group Inc. increased its stake in Abbott Laboratories by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock worth $6,308,944,000 after purchasing an additional 3,241,063 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Abbott Laboratories by 28.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock worth $569,830,000 after purchasing an additional 2,606,404 shares in the last quarter. 72.37% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently weighed in on ABT shares. Bank of America lifted their price target on Abbott Laboratories from $60.00 to $70.00 in a research note on Wednesday, January 24th. They noted that the move was a valuation call. Stifel Nicolaus lifted their price target on Abbott Laboratories from $63.00 to $71.00 and gave the stock a “buy” rating in a research note on Thursday, January 25th. Royal Bank of Canada reissued a “buy” rating and issued a $65.00 price target on shares of Abbott Laboratories in a research note on Tuesday, January 9th. Barclays reissued a “buy” rating and issued a $66.00 price target on shares of Abbott Laboratories in a research note on Monday, January 8th. Finally, Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research note on Tuesday, January 2nd. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Abbott Laboratories has a consensus rating of “Buy” and a consensus target price of $65.47.
Shares of NYSE ABT opened at $57.57 on Monday. Abbott Laboratories has a one year low of $42.31 and a one year high of $64.60. The stock has a market cap of $100,536.45, a price-to-earnings ratio of 23.03, a price-to-earnings-growth ratio of 1.71 and a beta of 1.49. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.26 and a quick ratio of 1.86.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.88% and a net margin of 1.74%. The firm had revenue of $7.59 billion during the quarter, compared to analyst estimates of $7.38 billion. During the same period last year, the company posted $0.65 EPS. The business’s quarterly revenue was up 42.3% compared to the same quarter last year. equities analysts expect that Abbott Laboratories will post 2.86 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be issued a dividend of $0.28 per share. The ex-dividend date is Thursday, April 12th. This represents a $1.12 annualized dividend and a dividend yield of 1.95%. Abbott Laboratories’s dividend payout ratio is 44.80%.
In other news, insider Brian J. Blaser sold 27,733 shares of Abbott Laboratories stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $62.26, for a total transaction of $1,726,656.58. Following the completion of the sale, the insider now directly owns 156,587 shares in the company, valued at approximately $9,749,106.62. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Daniel J. Starks purchased 40,037 shares of Abbott Laboratories stock in a transaction dated Tuesday, February 27th. The shares were purchased at an average price of $60.67 per share, with a total value of $2,429,044.79. Following the completion of the acquisition, the director now owns 6,943,348 shares in the company, valued at $421,252,923.16. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 124,261 shares of company stock valued at $7,559,987. 0.74% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/09/abbott-laboratories-abt-shares-sold-by-moors-cabot-inc.html.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.